🇺🇸 FDA
Pipeline program

Delamanid

242-12-233

Phase 2 small_molecule completed

Quick answer

Delamanid for Multidrug Resistant Tuberculosis is a Phase 2 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
Otsuka Beijing Research Institute
Indication
Multidrug Resistant Tuberculosis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials